Comparison of the therapeutic effects of combination regimens based on omadacycline or tigecycline in the treatment of carbapenem-resistant acinetobacter baumannii pneumonia
10.3760/cma.j.issn.1671-0282.2025.04.012
- VernacularTitle:基于奥马环素或替加环素的联合方案治疗耐碳青霉烯鲍曼不动杆菌肺炎的疗效比较
- Author:
Daoyuan JING
1
;
Xiuhua LI
;
Bingqiang SU
;
Bingwen ZHANG
Author Information
1. 金华市中心医院/浙江大学医学院附属金华医院急诊医学中心，金华 321000
- Keywords:
Pneumonia;
Acinetobacter baumannii;
Drug resistance;
Omadacycline;
Tigecycline
- From:
Chinese Journal of Emergency Medicine
2025;34(4):547-551
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the therapeutic effects of combination regimens based on omadacycline or tigecycline in the treatment of patients with carbapenem-resistant acinetobacter baumannii (CRAB) pneumonia.Methods:A retrospective analysis was performed on the case data of 92 patients diagnosed with CRAB pneumonia who were admitted to the Intensive Care Unit (ICU) of Jinhua Municipal Central Hospital between January 2022 and March 2024. Among these cases, 49 patients received combination therapy with omadacycline as the foundation (hereafter referred to as the omadacycline group),A total of 43 cases were treated with tigecycline-based combination therapy (hereafter referred to as the tigecycline group). The demographic and clinical data of the two patient groups, including pre- and post-treatment improvements in inflammatory markers, bacterial clearance rates, ventilator weaning success rates, and 28-day survival rates, were compared.Results:No significant differences were observed in the baseline characteristics between the two patient groups.The body temperature, white blood cell count, C-reactive protein levels, and procalcitonin concentrations in both groups of patients showed significant improvement after 72 hours of treatment.The differences observed were statistically significant ( P<0.05).Following the completion of the treatment regimen, the bacterial clearance rates in the omadacycline and tigecycline groups were 69.4% and 44.2%, respectively ( P = 0.015). Moreover, the success rates for weaning patients from ventilator support were 71.4% and 51.2%, respectively ( P = 0.046).However, no statistically significant difference was observed in the 28-day survival rate.No serious adverse drug reactions were observed in either of the groups. Conclusions:Both omadacycline- and tigecycline-based combination therapies have demonstrated significant efficacy in improving inflammatory markers in patients with CRAB pneumonia. There was no statistically significant difference in the 28-day survival rate between the two patient groups. Furthermore, combination therapy utilizing omadacycline can significantly enhance the efficacy of promoting negative conversion of the etiological agent,minimize the duration of mechanical ventilation.
